New independent analysis reveals significant business benefits of implementing DeepSights by Market Logic
The Forrester Consulting analysis, commissioned by Market Logic, details a wide range of specific impacts to business performance and the transformation of insights' strategic role within enterprises. Across a three-year period, the benefits identified include:
411% ROI
97% reduction in the time taken to answer insights requests
3% revenue growth attributed directly to the use of DeepSights
27% reduction in market research costs
>50% faster time to insights efficiency
50% cost avoidance for legacy IT solutions supporting insights
"The true business impact of applying AI and market intelligence, effectively and consistently into business operations is all too often not measured", said Dirk Wolf, CEO of Market Logic. "The Forrester TEI study provides an invaluable framework for tracking the positive benefits and material impact to business performance that our use-case specific Gen AI solution DeepSights has delivered. From significant operational efficiency gains all the way to business growth we are proud to see our customers share details of tangible business outcomes."
Specific calculations quoted in the study are derived by applying Forrester's TEI methodology to a composite organisation that is representative of the customers who participated in the analysis.
To download a full copy of the TEI study visit this page.
About Market Logic Software:
Market Logic is the leading SaaS provider of market intelligence and insights solutions. Our market intelligence and insights platform, powered by our special purpose AI for Insights technology DeepSights, allows insights teams and business decisions makers to transform trusted insights into impact at scale and speed. We've helped hundreds of consumer-focused brands across the globe to transform into insights-driven businesses. Market leaders such as Unilever, Vodafone, Bayer, and Tesco are driving innovation and making smarter market moves with the support of Market Logic.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
a few seconds ago
- Globe and Mail
Walker & Dunlop Arranges $160 Million Loan for Master Planned Community in the Coachella Valley
Walker & Dunlop, Inc. announced today that it has arranged a $160 million loan for a master planned community located in California's acclaimed Coachella Valley in the City of Rancho Mirage. The loan has a $27 million re-advance component for total proceeds of $187 million. This press release features multimedia. View the full release here: Walker & Dunlop Capital Markets, led by Sean Reimer, Aaron Appel, Jonathan Schwartz, Keith Kurland, Adam Schwartz, Dustin Stolly, Ari Hirt, and Christopher de Raet, were exclusive advisors to the borrower, EC Rancho Mirage Holdings Limited Partnership and its affiliates, to arrange the construction financing for the completion of the first phase of the community. Intervest Capital Partners and Builders Capital provided the capital. The master planned community, Cotino™, a Storyliving by Disney™ Community, is expected to contain approximately 1,900 residential units, a 24-acre lagoon with Crystal Lagoon s ® technology, a voluntary private club, a town center and various other amenities. 'Featuring a stunning backdrop of the Coachella Valley's natural beauty and close proximity to Palm Springs amenities, the desire to live in Rancho Mirage remains high,' said Reimer, managing director of New York Capital Markets at Walker & Dunlop. 'We are honored to work on this community, a groundbreaking project that blends unique lifestyle amenities and award-winning homebuilders. We look forward to seeing this extraordinary community come to life.' Walker & Dunlop is one of the top providers of capital to the U.S. multifamily market; in 2024 the firm originated over $30 billion in debt financing volume, including lending over $25 billion for multifamily properties. This vast experience has made them a top advisor on all asset classes for many of the industry's top developers, owners, and operators. To learn more about Walker & Dunlop's broad financing options, visit our website. About Walker & Dunlop Walker & Dunlop (NYSE: WD) is one of the largest commercial real estate finance and advisory services firms in the United States and internationally. Our ideas and capital create communities where people live, work, shop, and play. Our innovative people, breadth of our brand, and our technological capabilities make us one of the most insightful and client-focused firms in the commercial real estate industry.
Cision Canada
2 hours ago
- Cision Canada
WuXi Biologics Launches HEK 293 Stable Cell Line Platform WuXia293 Stable for Development and Manufacturing of Difficult-to-Express Molecules
WuXia293 Stable platform demonstrates high titer, human glycosylation and improved product quality by eliminating or significantly alleviating truncation in difficult-to-express molecules. WuXia293 Stable platform maintains stable expression and consistent product quality during long-term cell passages, enabling scalable clinical and commercial manufacturing. SHANGHAI, Aug. 11, 2025 /CNW/ -- WuXi Biologics ( a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of WuXia293 Stable, a new platform designed for the development and manufacturing of innovative, difficult-to-express molecules that are stably expressed in HEK293 cells. The platform, which demonstrates high titers, robust stability and superior quality, significantly enhances the developability and manufacturability of these molecules, offering a highly efficient CMC solution for biologics that are sophisticated in both structure and function. Conventionally, CHO cells have been widely utilized for recombinant protein expression with proven track record of high titers, and good developability and manufacturability. However, complex modalities may not be compatible with CHO expression system, resulting in low titer levels and truncation issues, due to the impact of some CHO-specific host cell proteins (HCPs), that compromise the quality and functionality of the protein products. In contrast, HEK293 cells can eliminate or significantly alleviate truncation issues in expressing complex molecules while maintaining high titer levels. WuXi Biologics developed WuXia293 Stable by leveraging its proprietary HEK293 cell line. Derived from WuXi Biologics' highly-vetted mammalian cell line development platform family WuXia™, WuXia293 Stable demonstrates productivity, quality and stability comparable to WuXia™ while maintaining full compatibility with its process, as shown by its robust growth and balanced metabolism. The platform achieves a fed-batch titer of up to 5.0 g/L for monoclonal antibodies while significantly improving purity. WuXia293 Stable offers flexible scalability in culture scale to meet the diverse needs of various research and pre-clinical development stages. Furthermore, the WuXia293 Stable cell line maintains stable expression and consistent quality during long-term cell passages, enabling scalable clinical and commercial manufacturing at 2000L scale for fed-batch and 1000L scale for perfusion. Moreover, WuXi Biologics offers a comprehensive suite of services for the WuXia293 Stable platform, including cell bank testing and viral clearance validation as part of its one-stop CMC solution. The launch of the WuXia293 Stable platform has further strengthened the service capabilities of WuXi Biologics' WuXia™ platform family. Besides WuXia293 stable, the WuXia™ platform has already derived multiple cell line development platforms, including WuXia ADCC Plus™ and WuXia RidGS™, to address customers' diverse requirements. Dr. Chris Chen, CEO of WuXi Biologics, commented, "We are excited to launch an industry-leading solution that significantly enhances the development of advanced therapeutics. WuXia293 Stable stands as a powerful testament to WuXi Biologics' unwavering commitment to our vision that every biologic can be made and exemplifies our dedication to technological innovation, which enables us to adeptly address the evolving needs of the biopharmaceutical industry. Once again we are reaffirming our promise to enable our clients in accelerating the delivery of innovative biologics to patients worldwide. " About the WuXia™ Cell Line Development Platform Family WuXia™ is a proven, high-yield (up to about 11 g/L) mammalian cell line platform family developed by WuXi Biologics. Accepted by regulatory agencies worldwide, the WuXia™ platform family have generated over 1000 cell lines expressing monoclonal and bispecific antibodies, fusion proteins, enzymes and other recombinant proteins for clinical and commercial manufacturing as of 2024. The WuXia™ platform family include WuXia ADCC Plus™ for developing and manufacturing afucosylated antibodies to elicit an enhanced ADCC response, WuXia RidGS™ for non-antibiotic cell line development, and the latest WuXia293 Stable for expressing difficult-to-express molecules built on HEK293 cell lines. The WuXia™ cell line development platform family continue to expand to cater to the diverse needs of global customers.
Toronto Star
3 days ago
- Toronto Star
KLEEN HY-DRO-GEN INC., Announces Launch of World's First Zero-Emissions Hydrogen Furnace
TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) — KLEEN HY-DRO-GEN INC., has officially announced the launch of KLEENHEAT™ hydrogen furnace, the world's first and only on-demand, zero-emissions home heating system powered by water. The announcement comes ahead of the company's anticipated listing on the Canadian Securities Exchange (CSE) this September, marking a major milestone in its journey to bring sustainable, home-grown hydrogen solution to the global stage. Now in its third year of testing, KLEENHEAT™ has been operating in a model home designed to educate the public on hydrogen heating-a safer, cleaner, zero-emissions alternative to fossil fuels. The system generates hydrogen and oxygen from water using electrolysis, producing only water vapor as a byproduct.
